Catalog No.
Product Name
Application
Product Information
Citations
-
Herbicide Agent
Fluroxypyr-meptyl is a synthetic phytohormone functioning primarily as a herbicide agent. It effectively targets broadleaf weeds by mimicking natural plant growth regulators, resulting in disrupted growth and eventual plant death. This compound is widely utilized in agricultural research for developing weed management strategies and studying plant hormonal interactions. -
Herbicide Safener
Herbicide Safener-4 is a herbicide safener that enhances the resistance of crops to herbicides while maintaining their efficacy against target weed species. It competitively binds to the acetolactate synthase (ALS) active site alongside Mesosulfuron-methyl. Additionally, Herbicide Safener-4 boosts the activity of critical enzymes, including glutathione S-transferase (GST), cytochrome P450 (CYP450), peroxidase (POD), superoxide dismutase (SOD), and ALS, promoting overall plant health. This compound is valuable for research in agricultural biotechnology and crop protection strategies. -
Endogenous Metabolite
D-Glucuronic acid sodium salt monohydrate is an endogenous metabolite primarily involved in the formation of anti-inflammatory proteoglycans. It plays a crucial role in promoting embryonic development and preventing cell aggregation. Upon metabolism to ethyl glucuronide, it activates Toll-like receptor 4 (TLR4), which is associated with pain regulation. Additionally, D-Glucuronic acid sodium salt monohydrate and its derivative glucurono-lactone function as liver detoxifiers and are recognized for their potential anti-tumor properties, making them valuable in various biological and pharmaceutical research applications. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-2 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). This benzothiophen-2-yl pyrazole carboxylic acid derivative demonstrates significant analgesic and anti-inflammatory properties, exhibiting COX-2 inhibitory activity with an IC50 of 0.01 μM and 5-LOX inhibitory activity with an IC50 of 1.78 μM. COX-2/5-LOX-IN-2 is a valuable tool for research applications aimed at understanding and modulating inflammatory pathways. -
CO/5-LO Inhibitor
P-8977 is a potent dual inhibitor of cyclooxygenase (CO) and 5-lipoxygenase (5-LO) with an IC50 of 0.01 µM and 0.53 µM, respectively. This compound exhibits significant anti-inflammatory activity, demonstrated by its ability to reduce ear edema. P-8977 is valuable for research focused on inflammatory skin conditions and their underlying biochemical mechanisms. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-5 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX). This compound effectively attenuates lipopolysaccharide-induced NF-κB activation in RAW 264.7 macrophages, highlighting its role in modulating inflammatory responses. COX-2/15-LOX-IN-5 exhibits significant anti-inflammatory and antioxidant properties, making it a valuable tool for research into inflammatory diseases and other related biological processes. -
Lipoxygenase/COX Inhibitor
SKF-105809 is a dual inhibitor of lipoxygenase and cyclooxygenase (COX), targeting key enzymes involved in the inflammatory pathway. This compound demonstrates a significant reduction in edema and inflammatory cell infiltration in murine models of ear, paw, and peritoneal inflammation. Additionally, SKF-105809 reduces the production of acute-phase reactive proteins in models of arthritis and exhibits analgesic effects in abdominal contraction assays while preventing ulceration. Its applications extend to the study of inflammatory and immune system disorders, including peritonitis and arthritis. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-1 is a dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX), exhibiting IC50 values of 10.65 μM for COX-1, 0.075 μM for COX-2, and 2.98 μM for 15-LOX. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its ability to modulate key enzymes involved in arachidonic acid metabolism positions COX-2/15-LOX-IN-1 as a promising candidate for therapeutic investigation in inflammatory conditions. -
5-LOX/COX-1 Inhibitor
Atractylochromene is a dual inhibitor targeting 5-lipoxygenase (5-LOX) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.6 μM and 3.3 μM, respectively. This compound serves as a valuable tool in research related to inflammatory pathways and can facilitate the study of related conditions influenced by leukotrienes and prostaglandins. Its inhibitory effects position Atractylochromene as a potential candidate for therapeutic exploration in inflammatory diseases. -
XO/COX/LOX Inhibitor
XO/COX/LOX-IN-1 is a potent inhibitor of xanthine oxidase, cyclooxygenases, and lipoxygenases. This compound exhibits significant anti-inflammatory activity, making it valuable for research in inflammation, cancer, and metabolic diseases. Its multifaceted inhibition profile positions XO/COX/LOX-IN-1 as a critical tool for exploring pathways involved in these pathological conditions. -
COX-2/LOX Inhibitor
COX-2/5-LOX-IN-4 is a potent dual inhibitor targeting both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), with IC50 values of 0.05 μM and 0.003 μM, respectively. By disrupting the arachidonic acid metabolism pathway, this compound effectively decreases the synthesis of prostaglandins and leukotrienes, leading to reduced inflammatory responses. In vivo studies using a rat ear edema model demonstrate its substantial anti-inflammatory activity, with intravenous doses resulting in up to 44% reduction in edema. COX-2/5-LOX-IN-4 is an important tool for investigating the mechanisms underlying inflammatory diseases. -
FAAH/COX Inhibitor
Carpro-AM1 is a dual-acting inhibitor targeting fatty acid amide hydrolase (FAAH) and selectively inhibiting cyclooxygenase (COX) enzymes. This compound exhibits an IC50 value of 94 nM for FAAH, demonstrating significant biological activity in regulating endocannabinoid signaling. Carpro-AM1 is suited for research applications focusing on pain management, inflammation, and the modulation of the endocannabinoid system. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-7 is a selective dual inhibitor targeting cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX) with IC50 values of 0.022 and 1.19 μM, respectively. It also demonstrates inhibition of COX-1 with an IC50 of 28.081 μM. This compound exhibits low cytotoxicity in human colorectal cancer cell lines (HT-29 and HCT116) with IC50 values exceeding 100 μM, and shows a non-ulcerogenic profile. COX-2/15-LOX-IN-7 is valuable for cancer research applications, facilitating the study of inflammatory pathways and therapeutic interventions. -
COX/5-LOX Inhibitor
CI-986 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), effectively preventing coronary vasoconstriction and the excessive production of leukotrienes, including LTB4 and LTC4. This compound exhibits notable anti-inflammatory and analgesic properties, making it a valuable tool for research into inflammation and cardiovascular diseases, including conditions like arthritis. CI-986's unique mechanism positions it as an important reagent in studies focused on the modulation of inflammatory pathways and vascular health. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-1 is a dual inhibitor targeting cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), represented as a benzothiophen-2-yl pyrazole carboxylic acid derivative. This compound exhibits significant analgesic and anti-inflammatory properties, demonstrating enhanced efficacy compared to traditional nonsteroidal anti-inflammatory drugs. COX-2/5-LOX-IN-1 displays potent inhibition of COX-1, COX-2, and 5-LOX, with IC50 values of 12.13, 0.4, and 4.96 μM, respectively, making it a valuable tool for research in pain and inflammation pathways. -
COX-2/5-LOX Inhibitor
Speranskoside is a dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase-15 (5-LOX), exhibiting an IC50 of 2.62 μg/mL for COX-2 and 5.51 μg/mL for 5-LOX. This compound demonstrates significant anti-inflammatory activity, making it valuable for the investigation of gastric ulcers and related disorders. Its unique mechanism of action provides a foundational tool for research into inflammatory pathways and therapeutic interventions. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-3 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX), exhibiting IC50 values of 45.73 µM for COX-1, 5.45 µM for COX-2, and 4.33 µM for 5-LOX. This compound is valuable for studying inflammatory diseases, as it effectively modulates the associated biochemical pathways. Its dual inhibition may provide insights into the complex roles of COX-2 and 5-LOX in mediating inflammatory responses. -
Meloxicam Metabolite
5'-Hydroxy meloxicam is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) meloxicam, primarily involved in modulating cyclooxygenase (COX) enzyme activity. This compound exhibits anti-inflammatory properties and is essential for understanding the pharmacokinetics and metabolism of meloxicam in biological systems. Its study contributes to research on drug efficacy and safety profiles in chronic inflammatory conditions. -
5-lipoxygenase Inhibitor
L-651896 is a potent inhibitor of 5-lipoxygenase, exhibiting significant anti-inflammatory and antiproliferative properties. By obstructing the production of leukotrienes and prostaglandins, L-651896 is useful in investigating skin diseases and various other inflammatory conditions. Its mechanism of action supports research aimed at understanding the role of lipid mediators in inflammatory pathways. -
5-lipoxygenase/ cyclooxygenase Inhibitor
PD 127443 is an inhibitor of both 5-lipoxygenase and cyclooxygenase, targeting critical enzymes involved in the inflammatory response. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research applications focused on understanding the mechanisms of inflammation and exploring potential therapeutic interventions in inflammatory diseases. -
COX/5-LOX Inhibitor
ZLJ-6 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), demonstrating potent oral bioactivity. With IC50 values of 0.73 μM for COX-1, 0.31 μM for COX-2, and 0.99 μM for 5-LOX, ZLJ-6 exhibits significant anti-inflammatory and analgesic properties. This compound is suitable for research applications aimed at investigating inflammatory pathways and potential therapeutic interventions. -
5-LOX/COX Inhibitor
(-)-Bornyl ferulate serves as a dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), displaying IC50 values of 10.4 μM and 12.0 μM, respectively. This compound demonstrates significant anti-inflammatory potential, making it useful for research focused on inflammation-related pathways and conditions. Its ability to modulate leukotriene and prostaglandin synthesis positions it as a valuable tool in the study of various inflammatory diseases and therapeutic interventions. -
CypD Inhibitor
CypD-IN-4 is a potent and selective inhibitor of cyclophilin D (CypD), exhibiting high affinity with an IC50 of 0.057 μM. This compound is valuable in researching various conditions related to oxidative stress, neurodegenerative diseases, liver dysfunction, aging processes, autophagy, and diabetes. CypD-IN-4 facilitates the exploration of CypD's role in these pathologies, providing insights into potential therapeutic strategies. -
CypD Inhibitor
CypD-IN-3 is a potent and selective inhibitor of cyclophilin D (CypD), demonstrating high affinity with an IC50 value of 0.01 μM. This compound is valuable for studying a range of biological processes and diseases, including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy, and diabetes. Its specificity towards CypD makes it an important tool for elucidating the role of this target in various cellular functions and pathological conditions. -
CypE Inhibitor
CypE-IN-1 is a highly potent and selective inhibitor of cyclophilin E (CypE), exhibiting an IC50 of 0.013 μM and a Ki value of 0.072 μM. This compound is valuable for investigating the role of CypE in various pathological conditions, including oxidative stress, neurodegenerative diseases, liver disorders, aging processes, autophagy, and diabetes. Researchers can utilize CypE-IN-1 to explore therapeutic strategies targeting CypE-related pathways. -
11β-HSD1 Inhibitor
INCB13739 is a selective and potent inhibitor of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1), exhibiting an IC50 of 3.2 nM in enzymatic assays and 1.1 nM in peripheral blood mononuclear cells (PBMC). This compound demonstrates significant potential for research in type 2 diabetes mellitus (T2DM) and obesity, targeting the regulation of glucocorticoid metabolism, which plays a critical role in metabolic conditions. Its tissue-specific action makes it a valuable tool for understanding 11β-HSD1-related pathways in metabolic disorders. -
Ser/Thr Protease Activator
Plasma kallikrein-IN-1 is a highly potent inhibitor of plasma kallikrein, exhibiting an IC50 of 0.5 nM. This compound selectively targets serine/threonine proteases, thereby modulating proteolytic pathways. It is primarily utilized in research exploring the roles of kallikrein in cardiovascular and inflammatory disorders. This compound is invaluable for studies aimed at understanding the therapeutic potential of kallikrein inhibition. -
Factor Xa Inhibitor
DPC423 free base is a selectively potent Factor Xa inhibitor, demonstrating inhibition constants (Kis) of 0.15 nM in humans and 0.3 nM in rabbits. It exhibits moderate selectivity with Kis of 60 nM against human trypsin, 61 nM against plasma kallikrein, and 6000 nM against thrombin. By inhibiting the formation of the prothrombinase complex, DPC423 reduces thrombin generation, thereby obstructing fibrin formation and platelet activation. This compound is valuable for research applications related to anticoagulation in arterial thrombosis. -
Kallikrein
Ono 3307 free base is a synthetic protease inhibitor that targets kallikrein and other serine proteases. It demonstrates protective effects against acute pancreatitis by inhibiting hyperamylasemia and pancreatic edema, while also reducing cathepsin B leakage from lysosomes in a dose-dependent manner. This compound has significant applications in research related to protease regulation and pancreatic function, making it valuable for studies exploring the pathophysiology of acute pancreatitis and related conditions. -
Somatostatin Receptor Antagonist
Cyclosomatostatin is a potent somatostatin receptor antagonist that specifically targets somatostatin receptor type 1 (SSTR1). This compound effectively inhibits SSTR1 signaling, leading to reduced cell proliferation, decreased ALDH+ cell population size, and diminished sphere formation in colorectal cancer cells. It serves as a valuable tool for research applications focused on understanding the role of somatostatin signaling in cancer biology. -
Somatostatin (1-28) Derivative
[Nle8] Somatostatin (1-28) is a derivative of somatostatin (1-28) in which norleucine substitutes for methionine at position 8. This compound enhances amylase release and elevates cyclic AMP levels in pancreatic acini. It is utilized in research to study pancreatic function and the regulatory mechanisms of peptide hormones in metabolic processes. -
Heme Oxygenase Inhibitor
Zn(II) Deuteroporphyrin IX 2,4 bis ethylene glycol is a potent inhibitor of heme oxygenase (HO), a key enzyme involved in the degradation of heme to bilirubin. By inhibiting HO activity, this compound can effectively reduce the release of hypothalamic hormones such as arginine vasopressin (AVP), oxytocin (OT), and atrial natriuretic peptide (ANP) under hyperosmotic conditions. Its application extends to research involving hyperbilirubinemia and the physiological implications of HO modulation. -
12-Lipoxygenase Metabolite
12(S)-HPETE, a metabolite of 12-lipoxygenase, plays a crucial role in regulating vascular tone. It induces the expression of c-Fos and c-Jun proteins while increasing activating protein 1 (AP-1) activity in vascular smooth muscle cells. This compound may be pivotal in vasomotor regulation, influencing interactions between endothelial cells and adjacent blood cells. 12(S)-HPETE is useful for investigating cerebrovascular tension in various research contexts. -
AhR Agonist
ZSTK3744 is an aryl hydrocarbon receptor (AhR) agonist that binds directly to AhR, leading to the upregulation of key target genes such as CYP1A1, CYP1B1, and TIPARP. This compound demonstrates notable cell growth inhibitory effects and induces apoptosis specifically in triple-negative breast cancer cells. Its anti-tumor properties make ZSTK3744 a valuable tool for investigating mechanisms underlying chemoresistance in triple-negative breast cancer. -
AHR Inhibitor
IK-175 is a selective aryl hydrocarbon receptor (AHR) inhibitor that prevents the translocation of AHR from the cytoplasm to the nucleus. This compound exhibits high specificity for AHR, distinguishing itself from other receptors, transporters, and kinases. IK-175 is primarily used in research applications focused on studying AHR-related pathways and their implications in various diseases, including cancer and immune responses. -
AHR Antagonist
6,2',4'-Trimethoxyflavone is a potent antagonist of the aryl hydrocarbon receptor (AHR). This compound effectively represses AHR-mediated gene induction, making it a valuable tool for studying AHR-related signaling pathways. Its biological activity supports research in fields such as toxicology, cancer biology, and environmental health. -
AHR Inhibitor
KYN-101 is a selective AHR inhibitor that is potent and orally active. This compound effectively reduces CYP1A1 mRNA expression, contributing to its role in mediating anti-cancer activity. Researchers can utilize KYN-101 to investigate the therapeutic potential in cancer biology and the modulation of AHR-related signaling pathways. -
AhR Agonist
VAF347 is a highly selective aryl hydrocarbon receptor (AhR) agonist that effectively activates AhR signaling pathways. It has been shown to inhibit the differentiation of CD14+CD11b+ monocytes from granulo-monocytic precursors, demonstrating significant anti-inflammatory activity. VAF347 is utilized in research related to immune modulation and the study of inflammatory responses. -
AHR Antagonist
CAY10464 is a selective aryl hydrocarbon receptor (AhR) antagonist with a high affinity, exhibiting a Ki value of 1.4 nM. This compound effectively inhibits AhR signaling, making it valuable for research applications related to toxicology, environmental studies, and the modulation of immune responses. CAY10464 serves as a crucial tool for investigating the role of AhR in various biological processes and disease mechanisms. -
AhR Agonist
AhR Agonist 2 is a highly potent agonist of the aryl hydrocarbon receptor (AhR), exhibiting an EC50 of 0.03 nM. This compound facilitates the nuclear translocation of AhR, leading to the activation of downstream gene transcription and enhancement of skin barrier repair mechanisms. AhR Agonist 2 is valuable for research applications focused on skin conditions, particularly psoriasis. -
AhR activator/Thyroid hormone synthesis and Dopamine beta-hydroxylase inhibitor
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR), functioning as an inhibitor of thyroid hormone synthesis and dopamine beta-hydroxylase activity. This compound promotes the invasion of bladder cancer cells by activating AhR transcription and upregulating the expression of CYP1A1 and CYP1B1, implicated in carcinogenesis. Additionally, 2-Mercaptobenzothiazole exhibits inhibition of thyroid peroxidase activity with an IC50 of 11.5 μM and induces significant histological changes in Xenopus laevis, including delayed metamorphosis. It also increases chromosomal aberrations in Chinese hamster ovary cells and inhibits norepinephrine synthesis in murine models, demonstrating its relevance in carcinogenic studies and neurobiological research. -
AHR Antagonist
CB7993113 is a potent antagonist of the aryl hydrocarbon receptor (AHR), exhibiting an IC50 value of 0.33 μM. This compound effectively binds to the AHR protein and prevents its nuclear translocation, thereby inhibiting the biological effects mediated by this receptor. CB7993113 demonstrates significant inhibitory activity, reducing polycyclic aromatic hydrocarbon (PAH)- and TCDD-induced reporter activity by 75% and 90%, respectively, making it a valuable tool for research into AHR-related signaling pathways and toxicological studies. -
AhR Ligand
10-Cl-BBQ is a high-affinity ligand for the aryl hydrocarbon receptor (AhR), exhibiting significant immunosuppressive activity. This compound facilitates the translocation of AhR from the cytosol to the nucleus and effectively activates AhR-regulated reporter genes at nanomolar concentrations. Its properties make 10-Cl-BBQ a valuable tool for research in immunology and toxicology, particularly in studies focusing on AhR signaling pathways. -
AHR Antagonist
AHR Antagonist 2 is a potent aryl hydrocarbon receptor (AHR) antagonist, displaying IC50 values of 885 pM for human AHR and 2.03 nM for mouse AHR. This compound is valuable for investigations into cancer biology and the modulation of immune responses, making it an important tool for research in immunology and oncology. -
AhR Ligand
Benz[a]anthracene is an aromatic hydrocarbon receptor (AhR) ligand, displaying a pIC50 value of 7.319. As a polycyclic aromatic hydrocarbon (PAH), it is important for studies investigating AhR-mediated biological processes and environmental toxicity. This compound is also relevant in assessing pollution impacts, particularly in samples from areas influenced by industrial activities such as aluminum smelting. -
AhR Agonist
Indolokine A5 is a potent AhR (Aryl hydrocarbon receptor) agonist that plays a significant role in various biological processes. This compound is of particular interest in research applications involving immunology, toxicology, and cancer biology, where AhR activation may influence cellular responses and signaling pathways. Its ability to modulate AhR activity makes Indolokine A5 a valuable tool for studying the effects of environmental contaminants and endogenous ligands on cellular function. -
AhR Activator
3-OH-Kynurenamine (dihydroiodide) is an aryl hydrocarbon receptor (AhR) activator that modulates the immune response. It enhances the expression levels of indoleamine 2,3-dioxygenase 1 (Ido1) and transforming growth factor-beta 1 (Tgfb1). Research indicates that it can alleviate skin inflammation in psoriasis mouse models and mitigate kidney damage in nephrotoxic lupus mouse models, making it a valuable tool in studying immune-related conditions. -
AHR Modulator
DiMNF (3',4'-Dimethoxy-αNF) is a selective modulator of the aryl hydrocarbon receptor (AHR). Acting as a competitive ligand with an IC50 of 21 nM, it exhibits antagonistic properties that can be harnessed in anti-inflammatory research. DiMNF is valuable for investigating the role of AHR in various biological processes and potential therapeutic applications. -
AhR Agonist
N-Methylscatole is an aryl hydrocarbon receptor (AhR) agonist known for its ability to activate this important transcription factor. It exhibits weak agonistic activity and no significant antagonistic properties. This compound can be utilized in research involving AhR-mediated pathways and the study of environmental chemicals affecting biological systems. -
AHR Antagonist
AHR Antagonist 5 is a potent aryl hydrocarbon receptor (AHR) antagonist with an IC50 of less than 0.5 μM. This compound effectively inhibits tumor growth, particularly when used in conjunction with the checkpoint inhibitor anti-PD-1. It serves as a valuable tool for research in cancer biology and the development of combination therapies targeting the immune response.
